TRIMTACs/TRIMGLUEs Portfolio
CNS and inflammatory disorders (protein aggregation diseases)
Key Facts
About Trimtech Therapeutics
Trimtech Therapeutics is an early-stage biotech leveraging a novel targeted protein degradation platform focused on the under-exploited ubiquitin ligase TRIM21. The company is developing two main therapeutic modalities, TRIMTACs and TRIMGLUEs, aimed at clearing toxic protein aggregates implicated in intractable CNS and inflammatory diseases. Led by a team of seasoned scientists and executives, the company is building a portfolio of degraders while actively engaging with the scientific and investment community through conferences and advisory board appointments. As a private, pre-clinical entity, its near-term focus is on advancing its platform and pipeline toward proof-of-concept.
View full company profile